Advertisement
Loading...

WuXi Biologics (Cayman) Inc.

2269.HKHKSE
Healthcare
Biotechnology
HK$34.62
HK$1.28(3.84%)
Hong Kong Market is Open • 10:34
Advertisement

WuXi Biologics (Cayman) Inc. (2269.HK) Stock Competitors & Peer Comparison

See (2269.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2269.HKHK$34.62+3.84%143.4B25.84HK$1.34N/A
6160.HKHK$171.50-3.00%231.3B64.23HK$2.67N/A
1801.HKHK$80.90-2.94%140.3B149.81HK$0.54N/A
9926.HKHK$115.90-1.86%106.6B-81.62-HK$1.42N/A
6990.HKHK$435.40-5.76%101.5B-224.43-HK$1.94N/A
1177.HKHK$4.95-0.80%88.5B33.00HK$0.15+1.82%
3759.HKHK$17.25-1.54%47.1B15.68HK$1.10+1.27%
1530.HKHK$18.52+0.11%46.3B4.68HK$3.96+1.35%
9995.HKHK$78.40-5.14%43.4B52.62HK$1.49N/A
2696.HKHK$63.25-7.66%34.4B36.14HK$1.75N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2269.HK vs 6160.HK Comparison June 2026

2269.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2269.HK stands at 143.4B. In comparison, 6160.HK has a market cap of 231.3B. Regarding current trading prices, 2269.HK is priced at HK$34.62, while 6160.HK trades at HK$171.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2269.HK currently has a P/E ratio of 25.84, whereas 6160.HK's P/E ratio is 64.23. In terms of profitability, 2269.HK's ROE is +0.11%, compared to 6160.HK's ROE of +0.12%. Regarding short-term risk, 2269.HK is less volatile compared to 6160.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2269.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions